Liraglutide was approved for weight management in the UK under the brand name Saxenda in 2015, making it the longest-established GLP-1 drug in obesity treatment. At its weight management dose of 3mg daily, it produces average weight losses of approximately 8 percent of body weight over 56 weeks, based on the SCALE Obesity and Pre-diabetes trial published in the New England Journal of Medicine in 2015. This is meaningfully less than semaglutide and considerably less than tirzepatide, which has led to a shift in prescribing preference toward the newer weekly injections in most clinical settings.
Daily Injection and Adherence
The most significant practical difference between liraglutide and the newer GLP-1 drugs is its requirement for daily rather than weekly injection. Clinical data on long-term adherence shows that daily injectable therapies have substantially higher discontinuation rates than weekly ones. The burden of daily self-injection, combined with the need to store the medication refrigerated, represents a practical challenge that reduces real-world effectiveness relative to trial conditions. Adherence in the SCALE trial, with its structured clinical support, was higher than adherence observed in real-world prescribing practice.
Gastrointestinal Side Effects
The gastrointestinal side effect profile of liraglutide is similar to semaglutide, though the incidence rates differ. In the SCALE trial, nausea affected approximately 39 percent of participants, vomiting 16 percent, diarrhoea 21 percent, and constipation 19 percent. As with semaglutide, GI side effects are most pronounced during the dose escalation phase and typically attenuate over several weeks. The dose escalation schedule for Saxenda starts at 0.6mg daily and increases by 0.6mg each week until reaching 3mg.
Cardiovascular, Thyroid, and Pancreatic Risks
Liraglutide carries the same class-wide boxed warning regarding thyroid C-cell tumours as semaglutide, based on rodent studies, and is contraindicated in patients with a history of medullary thyroid carcinoma or MEN2. The LEADER trial, a large cardiovascular outcomes trial published in the New England Journal of Medicine in 2016, found that liraglutide reduced major adverse cardiovascular events by 13 percent compared to placebo in adults with type 2 diabetes at high cardiovascular risk. This established cardiovascular benefit in the diabetic population and has informed the clinical positioning of the drug.
Pancreatitis risk is similar to semaglutide. Gallbladder disease, including cholelithiasis and cholecystitis, is increased relative to placebo, driven by the same mechanism of rapid weight loss concentrating cholesterol in bile. Injection site reactions including bruising, redness, and localised pain are more common with daily injections than with weekly ones simply due to the higher frequency of injections. Rotating injection sites reduces this risk.
Muscle Loss on Liraglutide
Because liraglutide produces less total weight loss than semaglutide or tirzepatide, the absolute amount of lean mass lost is also smaller. However, the proportional contribution of lean mass to total weight lost follows a similar pattern to the rest of the drug class. Without resistance training and adequate protein intake, a meaningful proportion of weight lost on liraglutide will be lean mass rather than fat. For adults over 35 already experiencing age-related muscle decline, this consideration applies equally regardless of which GLP-1 drug is prescribed.
- Average weight loss 8% of body weight over 56 weeks: considerably less than semaglutide or tirzepatide
- Daily injection requirement reduces real-world adherence compared to weekly alternatives
- Nausea (39%), diarrhoea (21%), vomiting (16%), and constipation (19%) are the most common side effects
- Thyroid C-cell tumour warning: same contraindications as semaglutide
- LEADER trial: 13% reduction in major cardiovascular events in high-risk diabetic adults
- Lean mass loss follows similar proportional pattern to semaglutide, with smaller absolute losses due to less total weight reduction
- Pancreatitis and gallbladder disease risks apply as with all GLP-1 drugs